Introduction to the Partnership
The Danish pharmaceutical company Novo Nordisk México and the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) have signed a collaboration agreement to boost the development of clinical studies in therapeutic areas focusing on cardiometabolic diseases and low prevalence conditions.
Objectives of the Collaboration
According to Novo Nordisk, this partnership aims not only to elevate Mexico’s scientific profile internationally but also to provide early access to innovative therapies for the population. The agreement emphasizes adherence to high ethical and regulatory standards, professional training, evaluation of new molecules, and generation of relevant clinical data for public health decision-making.
Novo Nordisk’s Commitment to Mexico
The pharmaceutical firm, celebrating 20 years in Mexico with nearly 500 employees, has invested 870 million pesos in clinical studies between 2019 and 2024. This commitment reflects their dedication to fostering scientific development in Mexico and promoting more innovative, accessible, and patient-centered medicine.
Quotes from Key Figures
Valney Suzuki, General Director of Novo Nordisk México, stated: “This partnership with the National Institute of Nutrition demonstrates our commitment to Mexico, its medical talent, and patients who deserve access to cutting-edge therapies. Together, we will build a healthier future.”
José Sifuentes Osornio, General Director of INCMNSZ, explained that clinical research generates new medical knowledge and translates it into better treatments and more effective patient care.
Benefits of the Collaboration
Sifuentes Osornio highlighted that the partnership with Novo Nordisk will enable INCMNSZ to strengthen its scientific capabilities, broaden the scope of its studies, and produce medical evidence addressing the most pressing health issues in the Mexican population.
Sifuentes Osornio’s Perspective
“This alliance with Novo Nordisk will allow us to expand our scientific capabilities and contribute robust evidence to the development of treatments addressing the real needs of our population,” Sifuentes Osornio emphasized.
Key Questions and Answers
- What is the purpose of the collaboration between Novo Nordisk and INCMNSZ? The partnership aims to advance clinical research in Mexico, focusing on cardiometabolic diseases and low prevalence conditions while elevating the country’s scientific profile internationally.
- How will this collaboration benefit the Mexican population? The alliance will provide early access to innovative therapies, strengthen scientific capabilities at INCMNSZ, and generate medical evidence addressing pressing health issues in Mexico.
- What does Novo Nordisk bring to this collaboration? With 20 years of presence in Mexico and nearly 500 employees, Novo Nordisk has invested 870 million pesos in clinical studies between 2019 and 2024, demonstrating their commitment to fostering scientific development in the country.
- How will this partnership impact medical research in Mexico? The collaboration will broaden the scope of clinical studies, enhance scientific capabilities at INCMNSZ, and produce medical evidence addressing the most urgent health concerns in the Mexican population.
